This study looks at how safe and effective BRIUMVI® (also called ublituximab-xiiy) is for people with relapsing multiple sclerosis (RMS), a condition where the immune system attacks the brain and spinal cord. Participants in this study must have a confirmed diagnosis of multiple sclerosis (MS) and should not have received BRIUMVI® before. BRIUMVI® is given through an infusion, which means medicine is delivered directly into the bloodstream through a vein.

To join, you must not have had any live vaccines, like those for chickenpox or measles, in the four weeks before starting BRIUMVI®. You shouldn't have any active infections like hepatitis B, and you can't be part of another MS treatment study at the same time. This study aims to gather real-world information from people who have been prescribed BRIUMVI®.

• Participants must have MS and be new to BRIUMVI® treatment.
• No live vaccines or infections are allowed before starting BRIUMVI®.
• Cannot join if in another MS treatment study.